Search
Everbright Securities Recommends: Boost Allocation in Hong Kong's Robust Pharmaceutical Stocks
2025-07-18 /
Read about 0 minute
Author：小编
Despite the ongoing contraction in valuation within Hong Kong's pharmaceutical sector, the Price-to-Earnings (PE) ratios of certain high-quality enterprises remain compelling. Innovative pharmaceutical firms are witnessing brisk Business Development (BD) transactions, and encouraging shifts are evident across niche segments and transforming enterprises. Investors are advised to prioritize the long-term investment potential of high-quality, low-valuation stocks.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
